- Market Capitalization, $K 9,916,097
- Shares Outstanding, K 70,527
- Annual Sales, $ 462,510 K
- Annual Income, $ -846,590 K
- 60-Month Beta 1.20
- Price/Sales 21.50
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+30.90 (+27.87%)since 04/14/22
| || |
+0.84 (+0.60%)since 02/17/22
| || |
+71.51 (+101.76%)since 05/17/21
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Biohaven Pharmaceutical Holding Company Ltd....
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog
Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.
An industry titan wants to buy the biotech for a whopping $11.6 billion.
Find out how the rest of the markets are behaving.
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. for $148.50 per share in cash is fair to Biohaven...
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies...
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven,...
Biohaven Pharmaceutical (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
|Biohaven Pharmaceutical Holding Ltd|
|Bioshares Biotech Products|
|Principal Healthcare Innovators Index|
|S&P Biotech SPDR|
|Nasdaq Biotechnology Ishares ETF|
|US Innovative Healthcare Ishares Evolved ETF|
|3rd Resistance Point||143.13|
|2nd Resistance Point||142.45|
|1st Resistance Point||142.12|
|1st Support Level||141.11|
|2nd Support Level||140.43|
|3rd Support Level||140.10|